Occurrence of Influenza Hemagglutinin Antibodies in the Polish Population during the Epidemic Season 2017/18

This study seeks to define the level of antihemagglutinin antibodies, using the hemagglutination inhibition assay (HAI), in the serum of patients, stratified into seven age groups, in Poland during the influenza epidemic season of 2017/18. A quadrivalent influenza vaccine has been introduced in Pola...

Full description

Saved in:
Bibliographic Details
Published inAdvances in experimental medicine and biology Vol. 1222; p. 69
Main Authors Hallmann-Szelińska, Ewelina, Szymański, K, Łuniewska, K, Masny, A, Kowalczyk, D, Sałamatin, R, Brydak, L B
Format Journal Article
LanguageEnglish
Published United States 01.01.2019
Subjects
Online AccessGet more information

Cover

Loading…
More Information
Summary:This study seeks to define the level of antihemagglutinin antibodies, using the hemagglutination inhibition assay (HAI), in the serum of patients, stratified into seven age groups, in Poland during the influenza epidemic season of 2017/18. A quadrivalent influenza vaccine has been introduced in Poland as of this epidemic season, making it possible for the first time to conduct the analysis for four antigens: A/Michigan/45/2015 (H1N1) pdm09, A/Hong Kong/4801/2014 (H3N2), B/Brisbane/60/2008 - Victoria lineage, and B/Phuket/3073/2013 - Yamagata lineage. We found that the level of individual antihemagglutinin antibodies was different among the seven age groups studied; with the highest in patients of 5-9 years and 10-14 years of age. Interestingly, the protection factor, defined as the percentage of people with the level of antihemagglutinin antibodies of at least 1:40 after vaccination or due to a previous infection, was the highest for the antigen A/Hong Kong/4801/2014 (H3N2) in the same age groups (74% and 75%, respectively). Taking into account the dismal 3.6% of the vaccinated population in Poland, these findings point toward the sustained presence of an immune system response in patients after a prior influenza virus infection.
ISSN:0065-2598
DOI:10.1007/5584_2019_443